Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$8.44 - $16.89 $139,943 - $280,053
-16,581 Closed
0 $0
Q4 2021

Mar 11, 2022

BUY
$14.7 - $19.89 $243,740 - $329,796
16,581 New
16,581 $261,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $710M
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Bradley Foster & Sargent Inc Portfolio

Follow Bradley Foster & Sargent Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bradley Foster & Sargent Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bradley Foster & Sargent Inc with notifications on news.